Homology Medicines
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Homology Medicines generated cash of -$18,677,000, which is more than the previous year. Cash used in financing activities reached the amount of $406,000 last year. Net change in cash is therefore -$18,276,000.
Cash Flow
| 2016 | -8.48M | -2.26M | 378.31K |
|---|---|---|---|
| 2017 | 6.47M | -81.52M | 115.22M |
| 2018 | -42.56M | -121.78M | 150.99M |
| 2019 | -91.35M | -51.79M | 158.21M |
| 2020 | -94.33M | 204.89M | 53.09M |
| 2021 | -109.75M | -50.78M | 52.16M |
| 2022 | -113.66M | 36.71M | 596K |
| 2023 | -18.67M | -5K | 406K |
0T6G.L Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 49.54M | 108.38M | 217.43M | 53.77M | 38.22M | 51.57M | 11.39M | 0 |
Operating activities | ||||||||
Net income | -53.74M | -5.00M | -95.76M | -128.69M | -103.91M | -55.57M | -29.99M | -8.04M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 586K | 2.59M | 9.54M | 8.90M | 6.31M | 1.28M | 684.21K | 239.79K |
Stock-based compensation expense | 1.42M | 1.23M | 753K | 13.24M | 7.63M | 0 | 277K | 162.28K |
| Deferred income tax benefit | 1.42M | 1.23M | 753K | 13.24M | 7.63M | 0 | 277K | 162.28K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 2.08M | -981K | -2.48M | 2.45M | -4.45M | 0 | 1.71M | 0 |
Cash generated by operating activities | -18.67M | -113.66M | -109.75M | -94.33M | -91.35M | -42.56M | 6.47M | -8.48M |
Investing activities | ||||||||
Purchases Of Investments | -73.24M | -157.46M | -97.39M | -19.99M | -286.39M | 0 | -79.56M | 0 |
Investments In Property Plant And Equipment | -228K | -1.28M | -2.39M | -3.73M | -21.83M | -24.93M | -1.95M | -1.98M |
Acquisitions Net | 0 | 130M | 48.39M | -208.62M | 29.96M | 0 | 0 | 0 |
Cash generated by investing activities | -5K | 36.71M | -50.78M | 204.89M | -51.79M | -121.78M | -81.52M | -2.26M |
Financing activities | ||||||||
Common Stock Issued | 184K | 596K | 52.16M | 53.09M | 158.21M | 0 | 115.24M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | -17.47K | 0 |
Repayments of term debt | 300K | 30M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 406K | 596K | 52.16M | 53.09M | 158.21M | 150.99M | 115.22M | 378.31K |
Net Change In Cash | -18.27M | -74.39M | -109.04M | 163.65M | 15.55M | -11.58M | 40.18M | 11.39M |
Cash at end of period | 31.26M | 33.98M | 108.38M | 217.43M | 53.77M | 39.99M | 51.57M | 11.39M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |